Kato Y, Ashida R, Ohgi K, Otsuka S, et al. Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases. Pancreas 2025 Mar 3. doi: 10.1097/MPA.0000000000002485.
PMID: 40019481